Johnny Wang 8/25/26 Johnny Wang 8/25/26

BeiGene: The Real Price of a Chinese Biotech Going Global

For fifteen years, BeiGene refused the safe path every other Chinese biotech took — and tried to build a truly global drug company from China. It won. Then, in its year of triumph, it changed its name.

Johnny Wang 7/15/26 Johnny Wang 7/15/26

Nearly 90% Protein Knockdown — and It Still Lost: The Real Deciding Factor Behind Ionis, Alnylam, and ATTR Cardiomyopathy

Johnny Wang 6/9/26 Johnny Wang 6/9/26

KRAS Cracked: The 40-Year Battle That Ended with a Standing Ovation at ASCO 2026

KRAS was called "undruggable" for 40 years. At ASCO 2026, daraxonrasib doubled survival in pancreatic cancer — and the room stood up for 42 seconds.

Johnny Wang 11/1/25 Johnny Wang 11/1/25

Lilly, J&J, and Jensen Huang's Healthcare Gambit: Two Roads to AI in Medicine

At GTC, pharma giants Eli Lilly and Johnson & Johnson both partnered with NVIDIA on AI—but took very different paths. Here's what their bets reveal about the future of medicine.